Celcuity Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 5 Aug 2026Drug approval is a major milestone that can lead to revenue and validate the company's research.
Drug approval is a major milestone that can lead to revenue and validate the company's research.
The company raised money to pay off debt and fund drug development, showing financial management.
Company prepared to raise money through stock or debt sales when needed for growth.
Company prepared to raise money through stock or debt sales when needed for growth.
Strong clinical trial results improve chances of drug approval and future sales success.
Board expansion and new independent director adds oversight and experience to company leadership.
Stocky reads Celcuity Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Celcuity Inc.'s most recent tracked filing was a 8-K/A on 15 Jul 2026: FDA approves REVTORPYK for advanced breast cancer treatment.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 5 Aug 2026.